Table 2.

HRs for prostate cancer-specific mortality associated with a panel of 22 SNPs in candidate genes in a discovery cohort (Seattle) and a validation cohort (Sweden)

Seattle cohortSwedish cohort
SNPChr.GeneAlleles1MAF2HR95% CIP (Q value)Model3MAF2HR95% CIP-value4Model3P-value5
rs11371001p31LEPRA/G0.270.290.14–0.600.0001 (0.26)Dom: ACP0.290.820.67–1.000.027Dom: ACP0.027
rs2286971p36PER3C/G0.110.250.10–0.600.0002 (0.26)Dom: ACP
rs6352611q25RNASELG/C0.360.220.07–0.650.0007 (0.56)Rec: ACP0.350.980.74–1.290.44Rec: A0.48
rs6278391q25RNASELG/T0.473.981.64–9.650.0004 (0.26)Dom: ACP0.471.221.00–1.500.024Dom: A0.22
rs45835142p21MSH2G/A0.382.491.21–5.100.01 (0.70)Dom: ACP0.430.980.81–1.18NSDom: ANS
rs46085772p21MSH2T/G0.172.041.36–3.070.002 (0.57)Tre: A0.210.930.80–1.09NSTre: ANS
rs5233492p23SRD5A2C/G0.290.490.28–0.860.01 (0.66)Dom: A0.321.150.94–1.40NSDom: ACP6NS
rs124679112p23SRD5A2C/T0.280.450.24–0.810.005 (0.57)Dom: A0.321.160.95–1.41NSDom: ACP6NS
rs117102773p21SEMA3FA/G0.093.711.75–7.900.001 (0.53)Dom: ACP0.080.860.66–1.11NSDom: ANS
rs112055q23HSD17B4A/G0.390.210.06–0.700.001 (0.61)Rec: ACP0.441.080.84–1.39NSRec: ACP6NS
rs20708745q31IL4C/T0.162.161.27–3.670.005 (0.57)Dom: A0.191.271.04–1.560.011Dom: ACP60.047
rs17999646p21TNF/LTAT/C0.210.390.20–0.770.003 (0.57)Dom: A0.200.910.74–1.130.20Dom: ACP0.44
rs46459598q24C-MYCA/G0.0400.00-inf.0.003 (0.57)Tre: ACP0.021.230.84–1.78NSTre: ANS
rs102915310q11CXCL12T/C0.310.220.07–0.750.005 (0.57)Tre: A
rs283968510q11CXCL12C/T0.1528.27.21–110.20.0003 (0.43)Rec: ACP0.101.310.49–3.530.30Rec: ACP60.34
rs230832710q26MGMTA/G0.130.320.13–0.780.004 (0.57)Tre: A0.130.920.76–1.120.20Tre: A0.20
rs1077853412q23CRY1T/C0.362.211.19–4.120.008 (0.57)Dom: A0.351.231.00–1.510.022Dom: ACP0.036
rs249475014q32AKT1C/G0.070.220.07–0.700.001 (0.50)Tre: ACP0.060.930.70–1.240.31Tre: ACP0.31
rs179981415q24CYP1A1C/A0.050.130.03–0.570.0003 (0.26)Tre: ACP0.031.470.86–1.28NSTre: ACP6NS
rs2548719q13XRCC1G/A0.360.490.31–0.770.003 (0.57)Tre: A0.350.950.83–1.080.20Tre: A0.40
rs91592719q13XRCC1A/G0.432.541.24–5.180.005 (0.57)Dom: A0.440.880.71–1.08NSDom: ACPNS
rs599389122q11ARVCFC/T0.050.210.07–0.610.0004 (0.26)Dom: ACP0.050.720.52–1.010.024Dom: A0.21
  • †These SNPs were not evaluated in the Swedish cohort due to genotyping failure.

  • 1Major/minor allele.

  • 2MAF: minor allele frequency, calculated from cases that did not die of prostate cancer.

  • 3Genetic model of best fit (Dom = dominant, Rec = recessive, Tre = trend) adjusted for age (A) alone, or age + clinicopathologic (ACP) factors (Gleason score, stage, diagnostic PSA level and primary treatment).

  • 4NS = not significant as the HR in the validation (Swedish) dataset is in the opposite direction as in the discovery (Seattle) dataset.

  • 5P-value for the Swedish dataset using the same best fitting genetic model and the same covariates as for the Seattle dataset.

  • 6Adjusted for age + clinicopathological factors as in footnote 3 above, excluding primary treatment.